Literature DB >> 24656623

Inflammatory markers in patients with rheumatoid arthritis.

A K Shrivastava1, H V Singh2, A Raizada3, S K Singh4, A Pandey5, N Singh4, D S Yadav3, H Sharma6.   

Abstract

BACKGROUND: Autoimmune diseases such as rheumatoid arthritis (RA) are the consequence of a persistent imbalance between pro- and anti-inflammatory immune mechanisms, leading to chronic inflammation. The objective of this study was to determine whether the high sensitive C-reactive protein (hs-CRP) and cytokines are elevated in RA patients and to investigate the relationship between these markers and disease activity in RA, measured by disease activity score 28 (DAS28).
METHODS: We studied 110 RA patients according to American College of Rheumatology revised criteria for RA, and 55 controls matched by age and sex. Serum levels of hs-CRP and cytokines interleukin (IL)-6, IL-10 and tumour necrosis factor-α (TNF-α) were estimated and correlated with the DAS28. Serum hs-CRP was assayed immunoturbidimetrically and cytokines were analysed by commercially available ELISA kit.
RESULTS: We found that RA patients had significantly higher levels of serum hs-CRP (p<0.001), IL-6 (p<0.001), TNF-α (p<0.001), and IL-10 (p<0.01) as compared to healthy controls. hs-CRP, IL-6 and TNF-α correlated positively (p<0.001) and IL-10 correlated negatively (p<0.01) with DAS28.
CONCLUSIONS: These results demonstrate that RA patients have high levels of inflammatory markers, and these levels are correlated with the DAS28. These findings suggest a possible role of these markers in the pathogenesis of RA. Moreover, these biomarkers can be used as markers of disease activity in the diagnosis and treatment of RA.
Copyright © 2013 SEICAP. Published by Elsevier Espana. All rights reserved.

Entities:  

Keywords:  Inflammation; Interleukin-10; Interleukin-6; Rheumatoid arthritis; Tumour necrosis factor-α; hs-CRP

Mesh:

Substances:

Year:  2014        PMID: 24656623     DOI: 10.1016/j.aller.2013.11.003

Source DB:  PubMed          Journal:  Allergol Immunopathol (Madr)        ISSN: 0301-0546            Impact factor:   1.667


  21 in total

1.  The fluence effects of low-level laser therapy on inflammation, fibroblast-like synoviocytes, and synovial apoptosis in rats with adjuvant-induced arthritis.

Authors:  Yueh-Ling Hsieh; Yu-Jung Cheng; Fang-Chuen Huang; Chen-Chia Yang
Journal:  Photomed Laser Surg       Date:  2014-12       Impact factor: 2.796

2.  Skeletal muscle stem cell characteristics and myonuclei content in patients with rheumatoid arthritis: a cross-sectional study.

Authors:  Rasmus Jentoft Boutrup; Jean Farup; Kristian Vissing; Michael Kjaer; Ulla Ramer Mikkelsen
Journal:  Rheumatol Int       Date:  2018-04-12       Impact factor: 2.631

3.  Early Prognostic Factors Associated with the Efficacy of Infliximab Treatment for Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate.

Authors:  Satoko Hayashi; Katsuya Suzuki; Keiko Yoshimoto; Masaru Takeshita; Takahiko Kurasawa; Kunihiro Yamaoka; Tsutomu Takeuchi
Journal:  Rheumatol Ther       Date:  2015-12-11

4.  C-reactive protein and the acute phase reaction in geriatric patients.

Authors:  Thomas Bertsch; Jakob Triebel; Cornelius Bollheimer; Michael Christ; Cornel Sieber; Klaus Fassbender; Hans Jürgen Heppner
Journal:  Z Gerontol Geriatr       Date:  2015-09-03       Impact factor: 1.281

5.  Serum Adenosine Deaminase as Inflammatory Marker in Rheumatoid Arthritis.

Authors:  Kiranmayi S Vinapamula; Srinivasarao V L N Pemmaraju; Siddartha Kumar Bhattaram; Aparna R Bitla; Suchitra M Manohar
Journal:  J Clin Diagn Res       Date:  2015-09-01

Review 6.  Epigallocatechin Gallate: A Review of Its Beneficial Properties to Prevent Metabolic Syndrome.

Authors:  Samuel Legeay; Marion Rodier; Laetitia Fillon; Sébastien Faure; Nicolas Clere
Journal:  Nutrients       Date:  2015-07-07       Impact factor: 5.717

7.  Putative IL-10 Low Producer Genotypes Are Associated with a Favourable Etanercept Response in Patients with Rheumatoid Arthritis.

Authors:  Heiko Schotte; Bernhard Schlüter; Hartmut Schmidt; Markus Gaubitz; Susanne Drynda; Jörn Kekow; Peter Willeke
Journal:  PLoS One       Date:  2015-06-24       Impact factor: 3.240

8.  Serum Tumor Necrosis Factor-Alpha as a Competent Biomarker for Evaluation of Disease Activity in Early Rheumatoid Arthritis.

Authors:  Mehreen Inam Illahi; Sofia Amjad; Syed Mehfooz Alam; Syed Tousif Ahmed; Murk Fatima; Moazzam A Shahid
Journal:  Cureus       Date:  2021-05-29

9.  Long noncoding RNA expression profile in fibroblast-like synoviocytes from patients with rheumatoid arthritis.

Authors:  Yu Zhang; Yu-Zhong Xu; Ning Sun; Jian-Hong Liu; Fang-Fang Chen; Xiao-Long Guan; Ang Li; Fei Wang; Qin-Fei Zhao; Hai-Yong Wang; Shu-Sheng Song; Wei Yu; Jian-Ning Zhao; Xiao-Jun Li
Journal:  Arthritis Res Ther       Date:  2016-10-06       Impact factor: 5.156

10.  Tumor Necrosis Factor Alpha Gene Polymorphism and Association With Its Serum Level in Iranian Population with Rheumatoid Arthritis.

Authors:  Hossein Hadinedoushan; Parisa Noorbakhsh; Hossein Soleymani-Salehabadi
Journal:  Arch Rheumatol       Date:  2016-07-27       Impact factor: 1.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.